Michael Pisetsky Sells 3,134 Shares of SiBone (NASDAQ:SIBN) Stock

Posted by Stanley Muller on Jul 8th, 2026

SiBone (NASDAQ:SIBN – Get Free Report) SVP Michael Pisetsky sold 3,134 shares of SiBone stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $16.71, for a total value of $52,369.14. Following the transaction, the senior vice president directly owned 277,375 shares of the company’s stock, valued at $4,634,936.25. This trade represents a 1.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Price Performance

SiBone stock opened at $17.30 on Wednesday. The firm has a market capitalization of $767.25 million, a PE ratio of -44.36 and a beta of 0.67. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The firm’s 50-day simple moving average is $14.87 and its 200 day simple moving average is $15.48. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The company had revenue of $52.59 million during the quarter, compared to analysts’ expectations of $51.16 million. On average, equities research analysts predict that SiBone will post -0.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on SIBN shares. Truist Financial reissued a “buy” rating and set a $18.00 price target (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. TD Cowen reduced their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SiBone in a research note on Thursday, July 2nd. Finally, Wall Street Zen cut SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, SiBone currently has an average rating of “Moderate Buy” and an average price target of $23.00.

Get Our Latest Stock Report on SiBone

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. ANTIPODES PARTNERS Ltd acquired a new stake in shares of SiBone during the fourth quarter worth $29,000. Royal Bank of Canada increased its stake in SiBone by 98.5% in the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after purchasing an additional 736 shares during the last quarter. Versant Capital Management Inc lifted its position in SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after buying an additional 887 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after buying an additional 1,941 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new stake in SiBone in the 4th quarter worth about $53,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About SiBone

(Get Free Report)

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.